sur VALBIOTIS (EPA:ALVAL)
Valbiotis Shows Strong Revenue Growth as 2025 Comes to a Close
Valbiotis SA experienced significant revenue growth in Q4 2025, marking a pivotal year in its commercial expansion. In France, the company strengthened its product portfolio and expanded its pharmacy distribution network, directly supplying 474 pharmacies, resulting in impressive sales figures. Key product launches in the ValbiotisPRO® range supported this growth.
Internationally, partnerships in Asia and the Middle East are underway, set to bolster Valbiotis' market presence. The strategic agreement with Aika in Asia and the distribution deal with Mena Nutrition in the Middle East represent critical steps in global expansion.
Looking forward, Valbiotis projects continued growth in 2026 with expanded operations in France and early revenue from international markets. The company remains committed to achieving its financial goals for 2027 and 2030.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de VALBIOTIS